Navigation Links
Essentialis to Submit SPA for Hypertriglyceridemia
Date:8/11/2009

CARLSBAD, Calif., Aug. 11 /PRNewswire/ -- Essentialis, Inc., a clinical stage pharmaceutical company, announced today its intention to file a Special Protocol Assessment (SPA) with the FDA for the pivotal study to support the NDA filing on its lead drug, DCCR, for the treatment of very high triglycerides. The proposed study would include 280 randomized subjects with the primary efficacy endpoint assessed at 12 weeks. This decision followed a productive Type C meeting with the FDA on July 30th, where the overall development plan for DCCR and the non-clinical package supporting the NDA were reviewed and discussed. Commenting on this development, Essentialis President and CEO Iain Dukes stated, "The submission of the SPA will bring us one step closer towards filing for approval of DCCR for the treatment of patients with very high triglycerides. This development, along with positive Phase 2 study results and the recent issuance of a US patent providing extensive protection to DCCR, underscores the tremendous clinical and commercial potential of this drug worldwide."

About DCCR

DCCR, diazoxide choline controlled release tablet, is an ATP-sensitive potassium channel agonist which has potential therapeutic utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing has demonstrated the drug's potential to lower triglycerides (TG), non-HDL cholesterol and LDL-cholesterol (LDL-C) while raising HDL-cholesterol. In addition, weight loss has been demonstrated in 2 investigator sponsored studies. A Phase 2, 8-week, placebo-controlled, double-blind study involving 90 patients, which was powered to be pivotal, demonstrated statistically significant reductions in triglycerides, without impacting LDL-C. In subjects with elevated LDL-C at baseline, DCCR reduced LDL-C levels. DCCR was generally well tolerated, and most AEs were mild to moderate, resolving without sequelae. US patent 7,572,789, containing claims to DCCR, was issued on August 11, 2009. Additional applications filed in the US and globally will further enhance the patent portfolio. Phase 2 and pivotal studies of DCCR in combination with a statin for the treatment of high triglycerides (TG between 200 and 500 mg/dL) are planned, and study synopses have been provided to the FDA.

About Hypertriglyceridemia

Very high triglycerides (TG greater than or equal to 500mg/dL) are a risk factor for developing pancreatitis. There are approximately 3.8 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides are fenofibrate and omega-3 fatty acids. While effective, these compounds cause significant elevations in LDL-C. High triglycerides (TG between 200 and 500 mg/dL) are a risk factor for coronary heart disease even after LDL-C targets have been achieved.

About Essentialis, Inc.

Essentialis, Inc. is a pharmaceutical company based in Carlsbad, CA. The Company's products are targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The Company's lead product, DCCR, is set to commence pivotal studies in subjects with very high triglycerides. Essentialis is actively exploring its partnering options for DCCR.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
2. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
3. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
4. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
5. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
(Date:9/20/2017)... ... 2017 , ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in ... 11, off work and rolled up their sleeves to help with relief efforts. The ... start the process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, whose ... creation of published author, Colleen Crispi, has owned four beauty salons and written a ... in real estate and cooking. , “The doctor’s office was only three blocks ...
(Date:9/19/2017)... NY (PRWEB) , ... September 19, 2017 , ... ... announced today the addition of strategic marketing leader, Denise Flannery, to its strategic ... Marketing, Brand and Management Consultant, Denise will work with clients across different industries ...
Breaking Medicine News(10 mins):